Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

被引:21
|
作者
Chalmers, James D. [1 ]
van Ingen, Jakko [2 ]
van der Laan, Roald [3 ]
Herrmann, Jean-Louis [4 ,5 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland
[2] Radboud Univ Nijmegen, Radboudumc Ctr Infect Dis, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[3] Insmed BV, Utrecht, Netherlands
[4] Univ Paris Saclay, UVSQ, Infect & Inflammat, INSERM, Montigny Le Bretonneux, France
[5] Grp Hosp Univ Paris Saclay, Hop Raymond Poincare, AP HP, Garches, France
来源
EUROPEAN RESPIRATORY REVIEW | 2021年 / 30卷 / 161期
关键词
PSEUDOMONAS-AERUGINOSA INFECTION; MECHANICALLY VENTILATED PATIENTS; TIME-KILL KINETICS; AVIUM COMPLEX; CYSTIC-FIBROSIS; CELL-WALL; AMIKACIN CONCENTRATIONS; ENCAPSULATED-AMIKACIN; RESISTANCE MECHANISMS; ABSCESSUS COMPLEX;
D O I
10.1183/16000617.0010-2021
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Occupational Exposures in Nontuberculous Mycobacterial Pulmonary Disease
    Blanc, Paul D.
    Balmes, John R.
    Redlich, Carrie
    CHEST, 2022, 162 (02) : E106 - E107
  • [42] Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan
    Namkoong, Ho
    Kurashima, Atsuyuki
    Morimoto, Kozo
    Hoshino, Yoshihiko
    Hasegawa, Naoki
    Ato, Manabu
    Mitarai, Satoshi
    EMERGING INFECTIOUS DISEASES, 2016, 22 (06) : 1116 - 1117
  • [43] The fungal burden in nontuberculous mycobacterial pulmonary disease
    Kumar, K.
    Nastase, A.
    Cuthbertson, L.
    Ellis, H. C.
    Loebinger, M. R.
    Moffatt, M. F.
    Cookson, W. O. C.
    THORAX, 2023, 78 (SUPPL_4) : A105 - A106
  • [44] Diagnosis and evaluation of nontuberculous mycobacterial pulmonary disease
    Kim, Hyung-Jun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2024, 67 (01): : 12 - 18
  • [45] Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease
    Kim, Hyung-Jun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (04) : 451 - 457
  • [46] Surgical Resection in Nontuberculous Mycobacterial Pulmonary Disease
    Taylor, Lauren J.
    Mitchell, John D.
    CLINICS IN CHEST MEDICINE, 2023, 44 (04) : 861 - 868
  • [47] Immunologic signatures of nontuberculous mycobacterial pulmonary disease
    Kwak, Nakwon
    Koh, Jaemoon
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [48] Current Therapy for Nontuberculous Mycobacterial Pulmonary Disease
    Hilary P. Steele
    Lisa M. Brumble
    Margaret M. Johnson
    Current Treatment Options in Infectious Diseases, 2015, 7 (4) : 342 - 351
  • [49] Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host
    Varley, Cara D.
    Streifel, Amber C.
    Bair, Amanda M.
    Winthrop, Kevin L.
    CLINICS IN CHEST MEDICINE, 2023, 44 (04) : 829 - 838
  • [50] The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
    Schildkraut, Jodie Anne
    Zweijpfenning, Sanne Maria Henriette
    Nap, Martijn
    He, Kun
    Dacheva, Elena
    Overbeek, Jetty
    Tostmann, Alma
    Wertheim, Heiman F. L.
    Hoefsloot, Wouter
    van Ingen, Jakko
    ERJ OPEN RESEARCH, 2021, 7 (03)